ABT vs RMD vs STE Stock Comparison

Abbott Laboratories, Resmed and Steris Prices as of Nov 13, 2026 Peers: Industry group
ABT Abbott Laboratories
$108.54 +5.4% 1M -16.0% 1Y
Market cap
$188.53B
P/E
40.1x
Revenue (TTM)
$48.23B
Div. yield
0.02%
Medical Devices Healthcare
3 wins
RMD Resmed Inc
$239.53 +1.7% 1M -5.0% 1Y
Market cap
$34.55B
P/E
21.7x
Revenue (TTM)
$5.73B
Div. yield
–
Medical Devices Healthcare
6 wins
STE STERIS plc
$264.36 +21.7% 1M +1.5% 1Y
Market cap
$25.72B
P/E
31.1x
Revenue (TTM)
$6.17B
Div. yield
0.01%
Medical Devices Healthcare
3 wins

Head to Head

12 decided of 12

Resmed leads on 6 of the 12 questions below (Resmed 6, Abbott Laboratories 3, Steris 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionABTRMDSTELeader
Larger companyMarket capitalisation $188.53B $34.55B $25.72B ABT
Cheaper on earningsLower P/E, profitable companies only 40.1x 21.7x 31.1x RMD
Cheaper on forward earningsLower price / next fiscal year consensus EPS 19.1x 18.5x 22.4x RMD
Faster revenue growthRevenue growth, trailing twelve months +10.0% +9.0% +8.1% ABT
More profitableNet margin, trailing twelve months 9.7% 27.8% 13.4% RMD
Better return on capitalReturn on invested capital 5.7% 22.0% 9.5% RMD
Less leveragedLower net debt / EBITDA 2.5x -0.3x 0.8x RMD
Higher dividend yieldTrailing dividend yield 0.02% 0.00% 0.01% ABT
Better 1-year returnPrice return, last 12 months -16.0% -5.0% +1.5% STE
Better 5-year returnAnnualised price return, 5 years -3.3%/yr -1.2%/yr +2.7%/yr STE
Less volatileAnnualised volatility, 1 year 28.5% 31.1% 26.8% STE
Higher overall scoreMean of the five percentile scores vs peers 56/100 80/100 70/100 RMD

Percentile Scorecard

ABTRMDSTE

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisABTRMDSTE
Valuation 74 #65 of 243 75 #62 of 243 73 #67 of 243
Growth 26 #168 of 228 60 #92 of 228 51 #113 of 228
Profitability 82 #41 of 222 99 #3 of 222 90 #23 of 222
Financial Health 33 #167 of 248 76 #61 of 248 64 #90 of 248
Shareholder Returns 65 #56 of 158 89 #18 of 158 75 #41 of 158
Overall 56 80 70
  • ABT ranked among 252 companies in Medical Devices and Diagnostics
  • RMD ranked among 252 companies in Medical Devices and Diagnostics
  • STE ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodABTRMDSTESPY
1 month +5.4%+1.7%+21.7% -2.0%
3 months -2.4%+6.7%+13.3% -2.8%
6 months +28.5%+18.6%+24.6% +2.0%
Year to date -13.4%-0.6%+4.3% +10.6%
1 year -16.0%-5.0%+1.5% +12.2%
3 years +11.8%+62.6%+28.5% +68.1%
3 years, per year +3.8%+17.6%+8.7% +18.9%
5 years -15.5%-6.0%+14.2% +61.4%
5 years, per year -3.3%-1.2%+2.7% +10.1%
10 years +170.4%+300.2%+307.9% +248.5%
10 years, per year +10.5%+14.9%+15.1% +13.3%

Risk

MeasureABTRMDSTESPY
Volatility, 1Y 28.5%31.1%26.8% 13.6%
Downside volatility, 1Y 27.8%33.9%25.4% 13.9%
Beta vs S&P 500, 1Y 0.070.510.39 1.00
Return / volatility, 1Y -0.56-0.160.06 0.90
Max drawdown, 5Y -41.6%-49.8%-36.5% -25.4%
From 52-week high -16.9%-13.2%-1.6% -3.2%
52-week high $130.59$275.96$268.65 $779.14
52-week low $82.56$182.82$199.40 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleABTRMDSTE
P/E now vs peer median 40.0xmedian 26.5x 21.5xmedian 26.5x 31.1xmedian 26.5x
P/S now vs peer median 3.9xmedian 2.7x 5.9xmedian 2.7x 4.2xmedian 2.7x
EV/EBITDA now vs peer median 20.3xmedian 18.4x 15.8xmedian 18.4x 16.2xmedian 18.4x
P/FCF now vs peer median 27.8xmedian 25.4x 20.9xmedian 25.4x 27.4xmedian 25.4x
P/B now vs peer median 3.6xmedian 2.5x 5.7xmedian 2.5x 3.5xmedian 2.5x
PEG now vs peer median -13.92median 0.98 0.99median 0.98 2.04median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsABTRMDSTE
Revenue $48.23B $5.73B $6.17B
Gross profit $27.46B $3.50B $2.75B
Operating income $6.65B $1.89B $1.17B
Net income $4.70B $1.59B $829.70M
Free cash flow $6.76B $1.61B $937.20M
R&D $3.31B $393.82M $118.40M
EPS (diluted) $2.70 $11.11 $8.47
Cash & equivalents $4.05B $1.01B $531.10M
Total debt $31.16B $409.60M $1.89B
Shares (diluted) 1.74B 143.41M 97.60M
Enterprise value $162.40B $29.00B $23.84B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricABTRMDSTE
P/E 40.0x 21.5x 31.1x
P/FCF 27.8x 20.9x 27.4x
P/Operating cash flow 21.2x 19.0x 19.9x
P/S 3.9x 5.9x 4.2x
P/B 3.6x 5.7x 3.5x
P/Tangible book 5.9x 6.1x 4.4x
EV/EBITDA 20.3x 15.8x 16.2x
EV/EBIT 32.3x 17.5x 23.1x
EV/Revenue 4.5x 5.8x 4.4x
EV/FCF 31.8x 20.6x 28.8x
EV/Operating cash flow 24.3x 18.7x 21.0x
PEG (3Y EPS CAGR) -13.92 0.99 2.04

Growth

14 metrics
MetricABTRMDSTE
Revenue growth (1Y) 10.0% 9.0% 8.1%
Revenue CAGR (3Y) 6.5% 9.4% 8.6%
Gross profit growth (1Y) 12.1% 11.0% 8.8%
Gross profit CAGR (3Y) 7.8% 13.2% 9.4%
Operating income growth (1Y) -13.8% 8.5% 20.2%
Operating income CAGR (3Y) 3.5% 18.2% -4.1%
Net income growth (1Y) -66.4% 10.8% 20.2%
Net income CAGR (3Y) -3.1% 20.7% 14.6%
EPS growth (1Y) -66.1% 13.5% 21.6%
EPS CAGR (3Y) -2.9% 21.8% 15.3%
Operating cash flow growth (1Y) -2.9% -6.0% -0.9%
Operating cash flow CAGR (3Y) 10.6% 23.7% 15.0%
Free cash flow growth (1Y) -2.3% -9.0% -2.5%
Free cash flow CAGR (3Y) 14.6% 25.5% 20.5%

Profitability

14 metrics
MetricABTRMDSTE
Gross margin 56.9% 61.1% 44.6%
EBITDA margin 21.9% 36.4% 27.0%
Operating margin 13.8% 33.0% 19.0%
Pretax margin 13.6% 35.1% 18.2%
Net margin 9.7% 27.8% 13.4%
FCF margin 14.0% 28.1% 15.2%
Operating cash flow margin 18.4% 30.9% 20.9%
Return on equity 9.1% 25.4% 11.4%
Return on assets 4.3% 18.5% 7.7%
Return on invested capital 5.7% 22.0% 9.5%
Return on capital employed 7.2% 26.1% 12.3%
Asset turnover 0.4x 0.7x 0.6x
Cash conversion (OCF / net income) 1.9x 1.1x 1.6x
Stock comp / revenue 1.5% 2.0% 1.0%

Financial Health

11 metrics
MetricABTRMDSTE
Debt / assets 28.8% 5.0% 17.7%
Debt / equity 0.6x 0.1x 0.3x
Net debt / EBITDA 2.5x -0.3x 0.8x
Debt / FCF 4.6x 0.3x 2.0x
Liabilities / assets 52.3% 27.6% 32.1%
Equity / assets 47.7% 72.4% 67.9%
Interest coverage 6.7x 81.1x 20.5x
Current ratio 1.5x 2.6x 2.1x
Quick ratio 0.8x 1.5x 1.3x
Cash ratio 0.3x 0.8x 0.4x
Altman Z-score 3.36 12.00 5.98

Shareholder Returns

7 metrics
MetricABTRMDSTE
Dividend yield 2.3% 1.1% 1.0%
Net buyback yield 0.7% 4.2% 1.3%
Shareholder yield 3.0% 5.3% 2.3%
Payout ratio (earnings) 92.0% – 30.4%
Payout ratio (FCF) 64.0% – 26.9%
Dividend growth (1Y) 6.9% – 9.5%
Dividend CAGR (3Y) 7.4% – 9.6%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusABTRMDSTE
Forward P/E 19.1xFY2026 18.5xFY2027 22.4xFY2026
EPS, next fiscal year $5.69FY2026 $12.92FY2027 $11.78FY2026
EPS growth, next FY +10.5%FY2026 +15.7%FY2027 +15.8%FY2026
EPS growth, the year after +10.2% +8.9% +11.9%
Revenue, next fiscal year $52.99BFY2026 $5.99BFY2027 $6.61BFY2026
Revenue growth, next FY +19.5%FY2026 +6.0%FY2027 +11.3%FY2026
Revenue growth, the year after -2.3% -3.8% -0.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersABTRMDSTE
Held by institutions 79.2% 68.7% 97.1%
Institutions holding 2,983 889 831
Change in shares held, QoQ +0.3% +3.2% +1.1%
Institutions buying 1,261 404 405
Institutions selling 1,379 360 302
Buyers to sellers 0.91 1.12 1.34

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ABTRMDSTE
ABT 1.00 0.41 0.49
RMD 0.41 1.00 0.50
STE 0.49 0.50 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ABT, RMD and STE?

Abbott Laboratories (ABT) is the largest by market capitalisation: Abbott Laboratories (ABT) $188.53B, Resmed (RMD) $34.55B, Steris (STE) $25.72B.

Which stock is cheaper, ABT, RMD and STE?

Resmed (RMD) trades on the lowest price-to-earnings ratio (Abbott Laboratories (ABT) 40.1x, Resmed (RMD) 21.7x, Steris (STE) 31.1x). On next year's consensus earnings, Resmed (RMD) is cheapest (Abbott Laboratories (ABT) 19.1x, Resmed (RMD) 18.5x, Steris (STE) 22.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Abbott Laboratories (ABT) grew revenue fastest over the trailing twelve months: Abbott Laboratories (ABT) +10.0%, Resmed (RMD) +9.0%, Steris (STE) +8.1%.

Which company is more profitable?

Resmed (RMD) has the highest net margin (Abbott Laboratories (ABT) 9.7%, Resmed (RMD) 27.8%, Steris (STE) 13.4%). On return on invested capital, Resmed (RMD) leads (Abbott Laboratories (ABT) 5.7%, Resmed (RMD) 22.0%, Steris (STE) 9.5%).

Which stock has performed better?

Over the past year Steris (STE) returned the most: Abbott Laboratories (ABT) -16.0%, Resmed (RMD) -5.0%, Steris (STE) +1.5%. Over five years, Steris (STE) compounded fastest (Abbott Laboratories (ABT) -3.3%/yr, Resmed (RMD) -1.2%/yr, Steris (STE) +2.7%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Abbott Laboratories (ABT) has the highest dividend yield: Abbott Laboratories (ABT) 0.02%, Resmed (RMD) 0.00%, Steris (STE) 0.01%. Resmed (RMD) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Steris (STE) has been the steadiest (Abbott Laboratories (ABT) 28.5%, Resmed (RMD) 31.1%, Steris (STE) 26.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ABT, RMD and STE?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Resmed (RMD) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.